June 24 (Reuters) - Capricor Therapeutics ( CAPR ) said
on Tuesday the U.S. Food and Drug Administration will not
convene its panel of outside experts before deciding on the
company's cell therapy for a heart condition associated with
Duchenne muscular dystrophy.
(Reporting by Mariam Sunny in Bengaluru)